Omega Therapeutics Q3 2024 GAAP EPS $(0.30) Misses $(0.28) Estimate, Sales $2.612M Beat $1.240M Estimate
Omega Therapeutics Q3 2024 GAAP EPS $(0.30) Misses $(0.28) Estimate, Sales $2.612M Beat $1.240M Estimate
Omega Therapeutics 2024年第三季度的GAAP每股收益爲-0.30美元，低於-0.28美元的預估，銷售額爲261.2萬美元，超過124萬美元的預估
Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. The company reported quarterly sales of $2.612 million which beat the analyst consensus estimate of $1.240 million by 110.56 percent. This is a 214.32 percent increase over sales of $831.000 thousand the same period last year.
Omega Therapeutics (納斯達克:OMGA)報告每股虧損$(0.30)，低於分析師一致預估$(0.28)的7.14%。公司報告的季度銷售額爲261.2萬，高於分析師一致預估的124萬，增長110.56%。這比去年同期的83.1萬銷售額增長了214.32%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間